Drug
Suptavumab KG
Suptavumab KG: highest development phase Phase 3, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Suptavumab 30 mg/kg NCT02325791 | Phase 3 | Respiratory Syncytial Virus Infections |
Latest
No recent events.
Follow Suptavumab KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.